Study of Isoquercetin (IQC-950AN) Plus Standard of Care Versus Standard of Care Only for the Treatment of COVID-19

Phase 2 Withdrawn Montreal Clinical Research Institute Pharmascience Inc. · collab Quercis Pharma AG · collab SCiAN Services, Inc. · collab

RandomizedParallel-groupSingle-blindTreatment

Summary

This is an open-label, randomized, multi-centre study where hospitalized subjects will be randomized in a 2:1 ratio to receive Isoquercetin (IQC-950AN) in addition to standard of care or standard of care only for 28 days following confirmation of a COVID-19 infection.

Timeline

Start: 2022-01
Primary completion: 2022-12
Completion: 2023-06

Publications

Background WHO Working Group on the Clinical Characterisation and Management of COVID-19 infection. A minimal common outcome measure set for COVID-19 clinical research. Lancet Infect Dis. 2020 Aug;20(8):e192-e197. doi: 10.1016/S1473-3099(20)30483-7. Epub 2020 Jun 12.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Isoquercetin	Small molecule	500 mg	Oral

Study of Isoquercetin (IQC-950AN) Plus Standard of Care Versus Standard of Care Only for the Treatment of COVID-19

Summary

Timeline

Publications

Drugs

Indications